Cabergoline for the prevention of ovarian hyperstimulation syndrome systematic review and meta analysis of randomized controlled trials

Thursday, February 20, 2014
Cabergoline reduces the occurrence of moderate-severe ovarian hyperstimulation syndrome and probably does not have a clinically relevant impact on clinical pregnancy or on the number of retrieved oocytes.

Read More

Translate »